Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
23 mrt 2007 - 14:27
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Large Scale Quinvaxem™ Vaccinations in Ethiopia
Bericht
Leiden, The Netherlands, March 23, 2007 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that children in the Ethiopian capital Addis Ababa, have received their first dose of Quinvaxem™ vaccine. Ethiopia is the most populous GAVI Alliance supported country to date to have Haemophilus influenzae type b (Hib) immunization included in its routine immunization programm
Datum laatste update: 02 september 2024